---
layout: default
title: Denosumab
parent: 僅模型預測 (L5)
nav_order: 59
evidence_level: L5
indication_count: 2
---

# Denosumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Denosumab: Drug Repurposing Evaluation — Insufficient Data to Complete Assessment

## One-Sentence Summary

Denosumab (DrugBank ID: DB06643) is included in this repurposing pipeline; however, the current Evidence Pack contains no original indication records, no TxGNN-predicted new indications, and no mechanism of action data. A standard repurposing evaluation cannot be completed at this time — the decision is **Hold** pending data remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 — pipeline output not yet generated |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Cannot the Evaluation Proceed?

Three critical data gaps block a complete repurposing assessment for Denosumab:

**1. No TxGNN predicted indications.** The `predicted_indications` array is empty. Without a target disease, all downstream analysis — clinical trial mapping, literature review, and mechanism plausibility scoring — cannot be performed. This is the single most important prerequisite for generating this report.

**2. No mechanism of action (MOA) data.** The MOA field was flagged as a High-severity gap (DG002). Understanding how Denosumab works at the molecular level is essential for evaluating whether any new indication is mechanistically plausible.

**3. No safety profile.** Package insert warnings and contraindications are absent (DG001, Blocking severity). Safety screening is a prerequisite before any clinical feasibility assessment can begin.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Denosumab's Evidence Pack is missing all three minimum inputs for a valid repurposing evaluation: TxGNN predictions, mechanism of action, and safety data. Proceeding without these would produce an assessment with no evidential basis.

**To proceed, the following is needed:**

- **[Blocking]** Run the TxGNN pipeline to generate predicted indications for Denosumab (DB06643)
- **[Blocking]** Download and parse the package insert PDF to extract warnings and contraindications
- **[High]** Query the DrugBank API for Denosumab's mechanism of action
- Re-submit the completed Evidence Pack for a full evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

